Table 1. Patient characteristics.
| Characteristics | Total n = 38 | Responder CR/PR, n = 23 | Non-responder SD/PD, n = 9 | P value |
|---|---|---|---|---|
| Age (yr) | 0.904 | |||
| Median (range) | 68 (35-89) | 67 (35-87) | 61 (45-89) | |
| Sex (%) | 0.121 | |||
| Male | 33 (86.8) | 21 (91.3) | 6 (66.7) | |
| Female | 5 (13.2) | 2 (8.7) | 3 (33.3) | |
| Smoking status (%) | 0.648 | |||
| Ever and current | 17 (44.7) | 10 (43.5) | 4 (44.4) | |
| Never | 17 (44.7) | 12 (52.2) | 2 (22.2) | |
| N-A | 4 (10.6) | 1 (4.3) | 3 (33.3) | |
| Tumor length (range, cm) (%) | 0.643 | |||
| <6 | 13 (34.2) | 7 (30.4) | 3 (33.3) | |
| ≥6 | 17 (44.7) | 10 (43.5) | 4 (44.4) | |
| N-A | 8 (21.1) | 6 (26.1) | 2 (22.2) | |
| Site of primary tumor (%) | 0.248 | |||
| Cervical | 3 (7.9) | 2 (8.7) | 1 (11.1) | |
| Upper | 7 (18.4) | 4 (17.4) | 3 (33.3) | |
| Middle | 10 (26.3) | 6 (26.1) | 2 (22.2) | |
| Lower | 18 (47.4) | 11 (47.8) | 3 (33.3) | |
| T stage (%) | 0.094 | |||
| 1 | 8 (21.1) | 3 (13.0) | 1 (11.1) | |
| 2 | 13 (34.2) | 7 (30.4) | 2 (22.2) | |
| 3 | 7 (18.4) | 9 (39.1) | 0 (0.0) | |
| 4 | 10 (26.3) | 4 (17.4) | 6 (66.7) | |
| N stage (%) | 0.342 | |||
| 0 | 8 (21.1) | 5 (21.7) | 1 (11.1) | |
| 1 | 13 (34.2) | 8 (34.8) | 2 (22.2) | |
| 2 | 7 (18.4) | 3 (13.0) | 4 (44.4) | |
| 3 | 10 (26.3) | 7 (30.4) | 2 (22.2) | |
| Stage (%) | 0.227 | |||
| I | 4 (10.5) | 3 (13.0) | 0 (0.0) | |
| II | 5 (13.2) | 3 (13.0) | 1 (11.1) | |
| III | 29 (76.3) | 17 (73.9) | 8 (88.9) | |
| Differentiation (%) | 0.472 | |||
| Well | 5 (13.2) | 3 (13.0) | 1 (11.1) | |
| Moderately | 22 (57.9) | 13 (56.6) | 5 (55.6) | |
| Poorly | 3 (7.9) | 1 (4.3) | 1 (11.1) | |
| N-A | 8 (21.0) | 6 (26.1) | 2 (22.2) | |
| Combined chemotherapy regimen (%) | 0.815 | |||
| 5-FU/cisplatin | 25 (65.8) | 16 (69.7) | 6 (66.7) | |
| Cisplatin | 7 (18.4) | 3 (13.0) | 1 (11.1) | |
| 5-FU | 3 (7.9) | 1 (4.3) | 2 (22.2) | |
| Radiotherapy alone | 3 (7.9) | 3 (13.0) | 0 (0.0) | |
| Pre-treatment Hb (g/dL) (Mean, SD) | 12.6, 1.7 | 12.7, 1.6 | 13.0, 1.7 | 0.662 |
| Pre-treatment albumin (g/dL) (Mean, SD) | 4.0, 0.6 | 4.1, 0.5 | 3.9, 0.6 | 0.443 |
| Pre-treatment LDH (U/L) (Mean, SD) | 100.3, 113.4 | 381.9, 136.9 | 431.0, 106.6 | 0.360 |
| SUVpeak (Mean, SD) | 10.9, 4.8 | 10.6, 5.7 | 11.1, 2.0 | 0.785 |
| SUVmax (Mean, SD) | 13.2, 6.1 | 12.9, 7.2 | 13.7, 3.2 | 0.867 |
| SUVmean (Mean, SD) | 5.4, 1.5 | 5.3, 1.7 | 5.9, 1.0 | 0.249 |
| MTV (Mean, SD) | 45.38, 36.1 | 39.75, 37.9 | 64.11, 39.1 | 0.098 |
| TLG (Mean, SD) | 265.50, 221.4 | 229.76, 199.7 | 388.74, 276.8 | 0.107 |
N-A, non-assessable; SD, standard deviation; 5-FU, 5-fluoropyrimidine; Hb, hemoglobin; LDH, lactate dehydrogenase; SUV, standardized uptake value; MTV, metabolic tumor volume; TLG, total lesion glycolysis.